A prospective, non-randomized multi-center clinical investigation of the Venus P-Valve™ for the treatment of pulmonary regurgitation with or without stenosis in patient with native outflow tracts.
Age range
12 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Safety of Venus P-Valve™ measured as probability of death/reoperation
Timeframe: month 12 follow-up
Safety of Venus P-Valve™ measured as probability of Major Adverse Cardiac and Cerebro-vascular Event (MACCE)
Timeframe: month 1 follow-up
Performance of Venus P-Valve™ measured as Success rate of valve placement and implantation
Timeframe: up to 30 days
Hemodynamic Performance of Venus P-Valve™ measured as the mean transvalvular pressure (mmHg)
Timeframe: 1 month
Performance of Venus P-Valve™ measured as change of pulmonary regurgitation (regurgitation classification by MRI)
Timeframe: baseline and month 6
Performance of Venus P-Valve™ measured as change of pulmonary regurgitation (regurgitation classification by transthoracic echocardiogram)
Timeframe: baseline, day 1, month 1, 6, 12 and annually thereafter to 3 years post procedure
Performance of Venus P-Valve™ measured as percentage of subjects with structural valve deterioration
Timeframe: month 6